GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-28. Numbers and descriptions here follow the published literature rather than marketing material.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
DszC is the first enzyme to intervene in the pathway in two sequential steps, catalyzing the double oxidation of DBT first into DBT-sulfoxide and then into DBT-sulfone. It requires FMNH2 as cofactor, which is supplied by DszD, and molecular oxygen. For that reason, the efficiency of this enzyme is dependent on the activity of DszD and on environmental oxygenation. The reaction catalyzed by DszC involves three phases: 1) molecular oxygen activation leading to the formation of a hydroperoxyflavin-intermediate (C4aOOH); 2) oxidation of DBT to DBTO; and 3) dehydration of FMN. DszC is the second least efficient enzyme in the pathway with a particularly low kcat of 1.6 ± 0.3 min−1. It is also severely affected from feedback inhibition caused mostly by HPBS and 2-HBP, the products of DszA and DszB respectively, For that reason, it has been targeted for optimization through enzyme engineering.
=== Center for Structural Biology === The Center for Structural Biology (CSB) is a "collaboratory" for X-ray crystallography, crystallization and protein engineering, and is a comprehensive structural biology resource for researchers at the University of Michigan and surrounding area. The center includes:
In addition to power and ground, these provide connections for data-in, data-out, clock and sometimes a strobe signal. These are connected in a daisy chain, which allows individual LEDs in a long LED strip light to be easily controlled by a microcontroller. Data sent to the first LED of the chain can control the brightness and color of each LED independently of the others. They are used where a combination of maximum control and minimum visible electronics are needed such as strings for Christmas and LED matrices. Some even have refresh rates in the kHz range, allowing for basic video applications. These devices are known by their part number (WS2812 being common) or a brand name such as NeoPixel. Filament An LED filament consists of multiple LED chips connected in series on a common longitudinal substrate that forms a thin rod reminiscent of a traditional incandescent filament. These are being used as a low-cost decorative alternative for traditional light bulbs that are being phased out in many countries. The filaments use a rather high voltage, allowing them to work efficiently with mains voltages. Often a simple rectifier and capacitive current limiting are employed to create a low-cost replacement for a traditional light bulb without the complexity of the low voltage, high current converter that single die LEDs need. Usually, they are packaged in bulb similar to the lamps they were designed to replace, and filled with inert gas at slightly lower than ambient pressure to remove heat efficiently and prevent corrosion.
Sources: en.wikipedia.org
===== Accelerated hair re-growth ===== Hair returns to the brand site with the next hair cycle in darker animals, but the loss after a month is permanent for pale-coated animals. Around two months after branding white hair will begin to grow on darker animals. This white hair often grows much more quickly than the rest of the coat and may eventually grow long enough to overlap the surrounding, pigmented hair. This boost occurs because growth follicles no longer compete for energy with the dormant or dead melanocytes. Under normal conditions, this competition is one of the key checks on the speed of hair growth.
The spontaneous decay of free protons has never been observed, and protons are therefore considered stable particles according to the Standard Model. However, some grand unified theories (GUTs) of particle physics predict that proton decay should take place with lifetimes between 1031 and 1036 years. The experimental lower bound for the mean lifetime is 0.96×1030 years. The mean lifetime measures decay to any product. Lifetimes for decay to specific products is also measured. For example, experiments at the Super-Kamiokande detector in Japan gave lower limits for proton mean lifetime of 1.6×1034 years for decay to an antimuon and a neutral pion, and 2.4×1034 years for decay to a positron and a neutral pion. Protons are known to transform into neutrons through the process of electron capture (also called inverse beta decay). For free protons, this process does not occur spontaneously but only when energy is supplied. The equation is:
== External links == PDB: 1RIE - X-ray structure of Rieske protein (water-soluble fragment) of the bovine mitochondrial cytochrome bc1 complex PDB: 1RFS - X-ray structure of Rieske protein (water-soluble fragment) of the spinach chloroplast cytochrome b6 fcomplex PDB: 1FQT - X-ray structure of Rieske-type ferredoxin associated with biphenyl dioxygenase from Burkholderia cepacia PDB: 1G8J - X-ray structure of Rieske subunit of arsenite oxidase from Alcaligenes faecalis PDB: 2I7F - X-ray structure of the Sphingomonas yanoikuyae B1 Rieske ferredoxin PDB: 2QPZ - X-ray structure of the Pseudomonas Naphthalene 1,2-dioxygenase Rieske ferredoxin InterPro: IPR005806 - InterPro entry for Rieske [2Fe-2S] region
=== Other === Eugenol is an ingredient in some fungicides and weed control products used in agricultural practices in the European Union. It is used in hundreds of household products, such as pesticides, pet care, laundry, cleaning, and paper or vehicle products.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.